User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Product Segments.....I-3
Anti-Alzheimer’s Disease Drugs.....I-3
Cholinesterase Inhibitors.....I-3
  
   NMDARA.....I-4
Anti-Parkinson’s Disease Drugs.....I-4
Dopaminergic Agents (Levodopa/Carbidopa).....I-4
Dopamine Agonists.....I-4
  
   Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine
  Amplifiers).....I-5
COMT Inhibitors.....I-5
MAO-B Inhibitors.....I-5
Dopamine Amplifiers.....I-5
  
   Current and Future Analysis.....II-1
1$100
   Key Brands in NDD Market.....II-2 1$100
   Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart).....II-3
Factors Affecting Market.....II-3
Major Growth Drivers.....II-3
Major Growth Inhibitors.....II-3
1$350
   Market Trends.....II-4
High Prevalence Rates Drive Market Growth.....II-4
Rapid Growth of Ageing Population.....II-4
Price Hikes and Government Caps.....II-4
1$100
   Combination Therapy Gaining Ground.....II-5
Research & Development.....II-5
Future Holds Promise.....II-5
1$100
   A Peek at Anti-AD Drug Market.....II-6
Impact of Dementia.....II-6
Epidemiology.....II-6
1$100
   Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart).....II-71$350
   Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart).....II-8

Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart).....II-8
Patient Growth Drivers.....II-8
Demographics Spell Opportunities.....II-8
1$350
   High Growth Rates for AD Drugs.....II-9
The Impact of Aricept.....II-9
Epic of NMDARA.....II-9
1$100
   Strengths.....II-10
Weaknesses.....II-10
1$100
   Future Therapies.....II-11
How Successful will the Late Stage Therapies be?.....II-11
A Geographic Milieu.....II-11
US.....II-11
Europe.....II-11
Japan.....II-11
1$100
   Alternative Drug Delivery Technologies Gaining Ground.....II-12
Transdermal Patch.....II-12
Domination of Acetyl Cholinesterase Inhibitors.....II-12
Dramatic Changes in Market Lie Ahead.....II-12
Advances in Next-Generation Treatments.....II-12
1$100
   Beta Amyloid Hypothesis.....II-13
Growth Drivers.....II-13
Ageing Baby Boomers Drive AD Market.....II-13
Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart).....II-13
1$350
   New Hypothesis Enables Effective Treatment.....II-14
Unmet Medical Needs Drive Market Growth.....II-14
Growth Inhibitors.....II-14
Link with Other Aliments.....II-14
Misdiagnosis.....II-14
Patient Awareness.....II-14
Medical Refunds.....II-14
1$100
   Competitive Landscape.....II-15
Pharmaceutical Majors Rule the Market.....II-15
Eisai/Pfizer.....II-15
Novartis.....II-15
Shire/Johnson & Johnson.....II-15
1$100
   Lundbeck/Forest.....II-16
Ipsen and UCB.....II-16
Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart).....II-16
1$350
   Year of Approval of AD Drugs in Leading Countries.....II-17
Compounds in Pipeline.....II-17
1$100
   Outlook for AD Drugs Market.....II-18
1$100
   An Alluring Market.....II-19
Prevalence.....II-19
Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart).....II-19
1$350
   Current Treatments.....II-20
New Medicines on the Horizon.....II-20
New Findings.....II-20
Product Launches Through 2009.....II-20
Dominance of Dopamine Agonists.....II-20
1$100
   Revival Revels in Other Anti-PD Drugs Segment.....II-21
COMT Inhibitors Growing Fastest.....II-21
Key Market Drivers.....II-21
Rising Awareness Magnifies Patient Base.....II-21
Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth.....II-21
The Debut of Stalevo.....II-21
Unmet Clinical Needs Show Mammoth Prospects.....II-21
1$100
   Key Market Inhibitors.....II-22
Limitations of Existing Medicines Inhibit Market Growth.....II-22
Under-Diagnosis Restrains Market Potential.....II-22
Generic Competition from L-Dopa and Carbidopa Curbs Market Growth.....II-22
Restricted Term of Dopamine Agonists Usage Delays Market Growth.....II-22
1$100
   Alzheimer's Disease.....II-23
Definition.....II-23
The Cause.....II-23
Finding AD.....II-23
Prevention.....II-23
1$100
   Treatment.....II-24
Parkinson’s Disease.....II-24
Definition.....II-24
Pathophysiology.....II-24
1$100
   Diagnosis.....II-25
Prevalence.....II-25
Treatment.....II-25
Surgical Intervention.....II-25
1$100
   Anti-Alzheimer’s’ Disease Drugs.....II-26
NMDARA.....II-26
1$100
   Memantine.....II-27
Cholinesterase Inhibitors (ChEIs).....II-27
Donepezil (Aricept).....II-27
Rivastigmine (Exelon).....II-27
1$100
   Galantamine Hydrobromide (Razadyne).....II-28
Tacrine (Cognex).....II-28
Other Alternatives.....II-28
Vitamin E.....II-28
Estrogen Therapy.....II-28
1$100
   Anti-Inflammatory Drugs.....II-29
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).....II-29
Antioxidants.....II-29
Vaccine.....II-29
Gingko Biloba.....II-29
Pure Medical Nicotine.....II-29
Anti-Parkinson’s Disease Drugs.....II-29
1$100
   Dopaminergic agents.....II-30
Levodopa/Carbidopa.....II-30
Dopamine Agonists.....II-30
Pergolide/Permax.....II-30
Bromocriptine/Parlodel.....II-30
Ropinirole/Requip.....II-30
1$100
   Pramipexole/Mirapex.....II-31
Cabergoline/Dostinex.....II-31
Apomorphine/Apokyn.....II-31
Other Dopamine Agonists.....II-31
Other PD Drugs.....II-31
COMT Inhibitors.....II-31
Tolcapone (Tasmar).....II-31
1$100
   Entacapone (Comtan).....II-32
MAO-B Inhibitors.....II-32
Dopamine Amplifiers.....II-32
Anticholinergics.....II-32
1$100
   Alzheimer’s Disease.....II-33
Key Pipeline Products.....II-33
Phenserine.....II-33
Ropern.....II-33
1$100
   Alzhemed.....II-34
MEM 1003.....II-34
Ampakine Compounds.....II-34
Parkinson’s Disease.....II-34
Key Pipeline Products.....II-34
1$100
   Adenosine A2a Antagonist.....II-35
Spheramine®.....II-35
Safinamide.....II-35
1$100
   O-1369.....II-36
1$100
   Risedronate Minimizes Risk of Hip Fractures in PD Patients.....II-37
Researchers Identify New Genes Responsible for AD.....II-37
Researchers Establish a New Link Between Loneliness and AD.....II-37
Researchers Try to Identify Early Stages of AD.....II-37
1$100
   SORL1 – The New Gene Found to be Responsible for AD.....II-38
Scientists Conduct Research Work on CERE-120 Gene Therapy.....II-38
Researchers Find New Snail Toxin for Nervous System Disorders.....II-38
Researchers Study Anti-PD Properties of Nicotine.....II-38
Researchers Establish New Link Between Pesticides and PD.....II-38
1$100
   Study Relates AD to the Quantity of Amyloid Protein.....II-39
Researchers Establish Effectiveness of Gene Therapy on AD Patients.....II-39
Scientists Use Electric Current to Treat PD Patients.....II-39
Scientists Prove Earlier Assumptions Wrong.....II-39
1$100
   Scientists Discover 2 Distinct Types of MCIs.....II-40
1$100
   Eisai Acquires MGI Pharma.....II-41
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Disease Treatment.....II-41
Merz Licenses Anti-Alzheimer’s Drug Technology from TAU.....II-41
Eisai Acquires Morphotek.....II-41
Transition Therapeutics Acquires NeuroMedix.....II-41
Evotec Teams Up with Boehringer Ingelheim.....II-41
1$100
   Siemens Signs Partnership Agreement with Wyeth.....II-42
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker.....II-42
Pfizer Joins Forces with Genizon.....II-42
Intellect Signs Licensing Agreement with IBL.....II-42
Boehringer Ingelheim signs R&D agreement with Ablynx.....II-42
1$100
   Avicena Teams Up with NINDS for Phase III Trial of PD-02.....II-43
Prana Begins Phase II clinical trial for PBT2.....II-43
Idera Teams Up with Merck.....II-43
1$100
   Merck Signs R&D Agreement with Neuroptix.....II-44
Neuro-Hitech Takes Over Q-RNA.....II-44
Neurogen Inks Licensing Agreement with Wyeth.....II-44
Acumen Revises License Agreement with Merck.....II-44
Newron Begins 2nd Phase III clinical trial for Safinamide.....II-44
1$100
   Newron Inks Global Licensing Agreement with Serono.....II-45
Pfizer Inks License Agreement with TransTech.....II-45
CeNeS Renews R&D Agreement with Tripos.....II-45
Athenagen Acquires Zapaq.....II-45
Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591.....II-45
1$100
   Teva Receives Health Canada Clearance for Azilect.....II-46
Valeant Introduces Zelapar Anti-PD Tablets in the US.....II-46
Merck to Halt Further Development of Anti-PD Drug Called Sarizotan.....II-46
Amarin Obtains Global Rights for New Apomorphine Formulation.....II-46
FDA Clears Exelon for Parkinson's Disease.....II-46
1$100
   Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112.....II-47
Pfizer Takes Over Rinat.....II-47
TorreyPines Begins 2nd Phase-I clinical trial for NGX267.....II-47
Kyowa Hakko Inks Licensing Agreement with Britannia.....II-47
Schwarz Pharma Receives EMEA Clearance for Neupro.....II-47
1$100
   Evotec Inks Licensing Agreement with Roche.....II-48
RheoGene Receives Funds from MJFF.....II-48
Eisai Initiates Phase I clinical trial for E2012.....II-48
Apokyn(R) Receives Approval in North America.....II-48
FDA Approves Azilect.....II-48
1$100
   Voyager Completes Phase II Study for of Leuprolide Acetate.....II-49
New Discovery for the Treatment of Alzheimer's Disease in Canada.....II-49
Ortho-McNeil Launches Razadyne™ ER.....II-49
1$100
   Flurizan Enters Phase II Clinical Trials.....II-50
Axonyx Releases Supplementary Results of Phase III Trial for Phenserine.....II-50
Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist.....II-50
BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson's Animal
  Models.....II-50
1$100
   Predix’s PRX-03140 Completes First Clinical Trial in Alzheimer's Disease.....II-51
Galapagos and Senexis Expand Collaboration.....II-51
Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch.....II-51
Neurologix Posts Interim Results of Phase I Gene Therapy.....II-51
GB Therapeutics Receives License for CHF1512.....II-51
Alzhemed™ Begins Phase III Trials.....II-51
1$100
   Newron Commences Phase III Trial With Safinamide.....II-52
Ceregene Bags FDA Approval for Gene Therapy Alzheimer's Study.....II-52
Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s.....II-52
FDA Grants Fast Track Designation.....II-52
Ester Neurosciences Joins Forces with Pharmacopeia.....II-52
1$100
   Boehringer Ingelheim (Germany).....II-53
Bristol-Myers Squibb Co. (USA).....II-53
Eisai Inc. (USA).....II-53
1$100
   Eli Lilly and Company (USA).....II-54
Forest Pharmaceuticals (USA).....II-54
GlaxoSmithKline PLC (UK).....II-54
1$100
   H. Lundbeck A/S (Denmark).....II-55
Merz Pharmaceuticals GMBH (Germany).....II-55
Novartis AG (Switzerland).....II-55
1$100
   Ortho-McNeil Neurologics, Inc. (USA).....II-56
Pfizer Inc (US).....II-56
Roche (Switzerland).....II-56
Shire Pharmaceuticals Group PLC (UK).....II-56
1$100
   Valeant Pharmaceuticals International (USA).....II-57
1$100
   Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-581$350
   Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-601$350
   Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-611$350
   Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-621$350
   Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment –Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-63

Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment –Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-63
1$350
   Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-64

Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012.....II-64
1$350
   Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-651$350
   Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-661$350
   Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-671$350
   Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart).....II-681$350
   Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-691$350
   Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....II-701$350
   Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-711$350
   Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-721$350
   Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment – Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-73

Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment – Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-73
1$350
   Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-74

Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-74
1$350
   Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-751$350
   Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-761$350
   Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-771$350
   Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-781$350
   Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-791$350
   Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-801$350
   Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-811$350
   Table 36: World Long-term Projections for Other PD Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-821$350
   Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-831$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
AD Market Overview.....III-1
Approval of Cholinesterase Inhibitors for MCI to Drive Market.....III-1
1$75
   Competitive Landscape.....III-2
Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart).....III-2
1$200
   Status of AD Drugs.....III-3
New Products in Clinical Trails.....III-3
1$75
   Prevalence.....III-4
Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart).....III-4
PD Therapies Market.....III-4
Levodopa/Carbidopa on Declining Spree.....III-4
Competition.....III-4
1$200
   Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart).....III-5
Patent Expiry Status.....III-5
Patent Expiry Status of Parkinson’s Disease Drugs in the US.....III-5
1$200
   New Brands and Pipeline Analysis.....III-6
PD Prevalence.....III-6
New Findings.....III-6
2$150
   Strategic Corporate Developments.....III-87$525
   Key Players.....III-153$225
   B. Market Analytics.....III-18
Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-18
1$200
   Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-191$200
   Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-20
1$200
   A. Market Analysis.....III-21
Current & Future Analysis.....III-21
Prevalence.....III-21
Strategic Corporate Developments.....III-21
1$75
   B. Market Analytics.....III-22
Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22
1$200
   Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-231$200
   Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-24
1$200
   A. Market Analysis.....III-25
Current & Future Analysis.....III-25
Prevalence.....III-25
Strategic Corporate Developments.....III-25
1$75
   B. Market Analytics.....III-26
Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-26
1$200
   Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$200
   Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-28
1$200
   A. Market Analysis.....III-29
Current & Future Analysis.....III-29
Prevalence.....III-29
Alzheimer’s Disease.....III-29
1$75
   Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart).....III-30
Parkinson’s Disease.....III-30
Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart).....III-30
1$200
   Competitive Scenario.....III-31
Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart).....III-31
Strategic Corporate Developments.....III-31
1$200
   B. Market Analytics.....III-32
Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-32
1$200
   Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-331$200
   Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-341$200
   Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-351$200
   Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-361$200
   Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-37
1$200
   A. Market Analysis.....III-38
Current & Future Analysis.....III-38
Prevalence.....III-38
Strategic Corporate Developments.....III-38
1$75
   Key Players.....III-391$75
   B. Market Analytics.....III-40
Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-42
1$200
   A. Market Analysis.....III-43
Current & Future Analysis.....III-43
Prevalence.....III-43
1$75
   B. Market Analytics.....III-44
Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-44
1$200
   Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-451$200
   Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-46
1$200
   A. Market Analysis.....III-47
Current & Future Analysis.....III-47
Prevalence.....III-47
New Findings.....III-47
1$75
   Strategic Corporate Developments.....III-48
Key Players.....III-48
2$150
   B. Market Analytics.....III-50
Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-50
1$200
   Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-511$200
   Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$200
   A. Market Analysis.....III-53
Current & Future Analysis.....III-53
Prevalence.....III-53
Strategic Corporate Developments.....III-53
1$75
   B. Market Analytics.....III-54
Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-54
1$200
   Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-551$200
   Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-56
1$200
   A. Market Analysis.....III-57
Current & Future Analysis.....III-57
Prevalence.....III-57
1$75
   B. Market Analytics.....III-58
Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-58
1$200
   Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$200
   Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$200
   A. Market Analysis.....III-61
Current & Future Analysis.....III-61
Prevalence.....III-61
New Findings.....III-61
Strategic Corporate Developments.....III-61
1$75
   Key Players.....III-622$150
   B. Market Analytics.....III-64
Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-64
1$200
   Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$200
   Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-66
1$200
   A. Market Analysis.....III-67
Current & Future Analysis.....III-67
Prevalence.....III-67
Strategic Corporate Developments.....III-67
2$150
   B. Market Analytics.....III-69
Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-69
1$200
   Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-701$200
   Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-711$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com